The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis

BMC Musculoskeletal Disorders

Research Article

Mohammed Z Cader¹  Andrew D Filer¹  Karim Raza¹  Christopher D Buckley¹ 

[1] MRC Centre for Immune Regulation, School of Immunity and Infection, The University of Birmingham, B15 2TT, Birmingham, UK;Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, B18 7QH, Birmingham, UK;

关键词: Rheumatoid Arthritis;    Rheumatoid Arthritis Patient;    Rheumatoid Factor;    Citrullinated;    Early Rheumatoid Arthritis;   

DOI  :  10.1186/1471-2474-11-187

 received in 2010-05-10, accepted in 2010-08-23,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundAnti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific for RA, but are not detectable in all RA patients. The aim of this study was to establish whether the clinical phenotypes of anti-CCP positive and negative disease are distinct at the earliest clinically apparent phase of disease.MethodsPatients were recruited from the Birmingham early inflammatory arthritis clinic. Participants were included in the current study if they presented within 3 months of symptom onset and fulfilled 1987 ACR criteria for RA at some point during an 18 month follow-up. Data were collected on demographic variables, joint symptoms and tender (n = 68) and swollen (n = 66) joint counts. CRP, ESR, rheumatoid factor and anti-CCP2 status were measured.Results92 patients were included (48 anti-CCP positive). The anti-CCP positive and negative groups were comparable in terms of demographic variables, inflammatory markers, joint counts and 1987 ACR classification criteria, except that more anti-CCP positive patients were rheumatoid factor positive (83.3% vs. 11.4%, p < 0.01). There was no significant difference in the pattern of joint involvement, except for an increased prevalence of knee joint swelling in anti-CCP positive patients (42.9% vs. 22.2%, p = 0.03).ConclusionsPatients with and without anti-CCP antibodies present in a similar way, even within three months of clinically apparent disease that eventually develops into RA.

【 授权许可】

Unknown   
© Cader et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.